CTXR Citius Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1506251 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-11.1%
TTM EPS YoY64.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-70.3%
ROA-34.3%
ROIC (approx.)-89.3%
Asset turnover—
Leverage & solvency
Liabilities / assets46.6%
Debt / equity0.00x
Current ratio0.84x
Interest coverage-127.24x
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-8.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-06-30 | 2026Q2*2026-03-31 | 2026Q1*2025-12-31 | 2025Q4*2025-09-30 | 2025Q3*2025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.49M | $1.67M | $3.94M | — | — | — | — | — |
| Cost of revenue | $491,843 | $328,878 | $789,208 | — | — | — | — | — |
| Gross profit | $1.00M | $1.34M | $3.15M | — | — | — | — | — |
| R&D expense | $1.05M | $1.63M | $1.60M | $1.64M | $1.62M | $3.77M | $2.13M | $2.91M |
| SG&A expense | $6.15M | $26.39M | $5.72M | $3.91M | $4.45M | $4.79M | $5.39M | $5.49M |
| Operating income | -$11.73M | -$32.19M | -$9.02M | -$8.44M | -$8.79M | -$11.26M | -$10.04M | -$11.05M |
| Interest expense | $198,333 | $33,031 | $155,538 | $95,520 | $172,262 | — | — | — |
| Pretax income | -$12.03M | -$28.34M | -$9.13M | -$8.48M | -$8.94M | -$11.25M | -$10.02M | -$10.93M |
| Income tax | -$107,347 | -$231,210 | $264,240 | $264,240 | $264,240 | $264,240 | $264,240 | $144,000 |
| Net income | -$8.86M | -$21.23M | -$8.22M | -$7.96M | -$8.79M | -$11.51M | -$10.28M | -$11.08M |
| EBITDA | — | — | — | — | — | — | — | -$11.05M |
| EPS (basic) | -0.34 | -0.95 | -0.38 | — | -0.80 | -1.27 | -1.30 | — |
| EPS (diluted) | -0.34 | -0.95 | -0.38 | — | -0.80 | -1.27 | -1.30 | — |
| Weighted avg. shares (diluted) | 26.17M | 22.38M | 21.50M | — | 11.01M | 8.58M | 7.49M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $17.01M | $4.59M | $7.72M | $4.25M | $6.09M | $26,410 | $1.10M | $3.25M |
| Receivables | $686,235 | $1.08M | $4.05M | — | — | — | — | — |
| Inventory | $22.63M | $22.66M | $22.64M | $22.29M | $17.21M | $15.34M | $14.38M | $8.27M |
| Current assets | $43.33M | $31.69M | $37.95M | $27.93M | $24.61M | $18.37M | $18.33M | $14.22M |
| Goodwill | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M |
| Total assets | $142.26M | $132.54M | $140.39M | $130.94M | $127.68M | $121.48M | $120.70M | $116.65M |
| Current liabilities | $51.65M | $55.02M | $38.21M | $44.91M | $51.84M | $49.88M | $44.81M | $35.81M |
| Total liabilities | $66.35M | $63.46M | $46.92M | $53.41M | $60.12M | $57.91M | $51.78M | $42.55M |
| Shareholders' equity | $66.61M | $61.54M | $79.96M | $67.55M | $65.06M | $60.66M | $65.41M | $70.08M |
| Shares outstanding | 27.45M | 22.38M | 22.38M | 18.07M | 14.48M | 8.76M | 7.73M | 7.25M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.68M | -$1.30M | -$13.01M | -$11.88M | -$5.41M | -$4.54M | -$4.73M | -$5.91M |
| Investing cash flow | -$2.00M | -$600,000 | -$4.40M | — | — | — | — | — |
| Financing cash flow | $23.09M | -$1.23M | $20.88M | $15.79M | $11.47M | $3.47M | $2.57M | -$3.75M |
| Depreciation & amortization | — | — | — | — | — | — | — | $0 |
| Stock-based compensation | $3.81M | $3.79M | $4.28M | $2.89M | $2.72M | $2.70M | $2.52M | $2.64M |
Free plan shows the latest 8 periods; Pro shows all 63 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.